摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,5-二氟苯并硫代肼盐酸盐 | 1018690-17-9

中文名称
2,5-二氟苯并硫代肼盐酸盐
中文别名
——
英文名称
2,5-difluorothiobenzoyl hydrazide; hydrochloride
英文别名
2,5-difluorothiobenzoyl hydrazide hydrochloride;2,5-difluoro-benzothiohydrazide hydrochloride;2,5-Difluorobenzothiohydrazide hydrochloride;2,5-difluorobenzenecarbothiohydrazide;hydrochloride
2,5-二氟苯并硫代肼盐酸盐化学式
CAS
1018690-17-9
化学式
C7H6F2N2S*ClH
mdl
——
分子量
224.662
InChiKey
QPJHPKRVJASBSJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.53
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    70.1
  • 氢给体数:
    3
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY<br/>[FR] DÉRIVÉS DE 1,3,4-THIADIAZOLE SPIRO-CONDENSÉS POUR INHIBER L'ACTIVITÉ DE LA KINÉSINE KSP
    申请人:SCHERING CORP
    公开号:WO2009052288A1
    公开(公告)日:2009-04-23
    The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. Formula I [Chemical formula should be inserted here as it appears on abstract in paper form.]
    本发明涉及以下式(I)的化合物(其中X、R1、R2、R3、p、E、环A和环B的定义如本文所述)。本发明还涉及包括这些化合物的组合物(包括药学上可接受的组合物),单独或与一个或多个额外治疗剂的组合物,并且涉及它们在抑制KSP动力蛋白活性以及治疗与KSP动力蛋白活性相关的细胞增殖性疾病或紊乱的用途的方法。Formula I [化学式应按照纸质形式中的摘要插入在此处。]
  • [EN] SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS<br/>[FR] DÉRIVÉS DE SPIRO 1,3,4-THIADIAZOLINE INHIBITEURS DE KSP
    申请人:SCHERING CORP
    公开号:WO2010132520A1
    公开(公告)日:2010-11-18
    The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity.
    本发明涉及下式(I)的化合物(其中X、R1、R2、R3、p、环A和环B的定义如本文所述)。本发明还涉及包括这些化合物的组合物(包括药用组合物),单独或与一个或多个额外治疗剂结合使用的方法,以及用于抑制KSP肌动蛋白活性和治疗与KSP肌动蛋白活性相关的细胞增殖性疾病或疾病的方法。
  • MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF
    申请人:Ahrendt Kateri
    公开号:US20100041719A1
    公开(公告)日:2010-02-18
    This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment of various disorders.
    本发明涉及有丝分裂动力蛋白酶抑制剂,特别是KSP的抑制剂,以及制备这些抑制剂的方法。本发明还提供包括本发明抑制剂的药物组合物,以及利用这些抑制剂和药物组合物治疗各种疾病的方法。
  • Mitotic kinesin inhibitors and methods of use thereof
    申请人:Array Biopharma Inc.
    公开号:US08324257B2
    公开(公告)日:2012-12-04
    This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment of various disorders.
    本发明涉及有丝分裂动力蛋白酶抑制剂,尤其是KSP的抑制剂,以及制备这些抑制剂的方法。本发明还提供了包括本发明抑制剂的制药组合物和利用这些抑制剂和制药组合物治疗各种疾病的方法。
  • Synthesis, determination of absolute configuration, and biological evaluation of spiro-fused thiadiazoline inhibitors of kinesin spindle protein (KSP)
    作者:Angie R. Angeles、Liping Yang、Chaoyang Dai、Andrew Brunskill、Andrea D. Basso、M. Arshad Siddiqui
    DOI:10.1016/j.tetlet.2010.09.066
    日期:2010.12
    A facile and highly convergent synthesis of biologically active spiro-fused thiadiazoline KSP inhibitors is reported. The highlights of the synthesis include the Michael reaction and cyclization of thiosemicarbazone to 1,3,4-thiadiazoline. This chemistry lends itself to the preparation of (+)-2, a potent and orally bioavailable anti-cancer agent, and to the development of a structure-activity relationship program. (C) 2010 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐